Drugs / NKR-2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03370198 | Oct 2017 → Jan 2018 | metastasis from malignant tumor of colon | Celyad Oncology SA | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03466320 | Sep 2018 → Feb 2021 | acute myeloid leukemia, myelodysplastic syndrome | Celyad Oncology SA | Completed | No outcome recorded |
| Phase 1/2 | NCT03018405 | Dec 2016 → May 2021 | acute myeloid leukemia, plasma cell myeloma | Celyad Oncology SA | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKR-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03018405 ↗ |
| Modality | Cell therapy | “NKR-2 (modified T cells)” NCT03370198 ↗ |
| Route | Other | “hepatic transarterial administration” NCT03370198 ↗ |